The efficacy of rituximab in refractory myositis: the jury is still out.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

1. Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025
   Pooled it
2. Rituximab in myositis: where are we now? A survey of current usage.Rheumatology (Oxford, England) · 2023
   Article
3. Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020
   Review
4. Autoimmune Myopathies: Updates on Evaluation and Treatment.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018
   Review
5. The Vasculopathy of Juvenile Dermatomyositis.Frontiers in pediatrics · 2018
   Review
6. Current Classification and Management of Inflammatory Myopathies.Journal of neuromuscular diseases · 2018
   Review
7. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.Clinical and experimental immunology · 2014
   Review
8. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.Rheumatic diseases clinics of North America · 2013
   Review
9. [Established medications : new areas of application].Zeitschrift fur Rheumatologie · 2013
   Review

Corrections and comments

• Comment on
  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.2013

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as